Market Overview:
The global organ transplant anti-rejection medications market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of organ failures, rising demand for organ transplants, and technological advancements in the field of organ transplantation. The global market for organ transplant anti-rejection medications is segmented on the basis of type into kidney transplant anti-rejection medications, bone marrow transplant anti-rejection medications, liver transplant anti-rejection medications, heart transplant anti-rejection medications, lung transplantsanti rejection medication and other types. On the basis of application, this market is segmented into hospital pharmacy, retail pharmacy,, online pharmacy and other applications. Geographically speaking,, this market is segmented into North America,, Latin America,, Europe Asia Pacific and Middle East & Africa (MEA). Of these regions,.
Product Definition:
Organ transplant anti-rejection medications are a type of medication that is used to help prevent the body from rejecting a transplanted organ. These medications work by suppressing the immune system, which helps to keep it from attacking the new organ. Organ transplant anti-rejection medications are important because they help to ensure that the transplanted organ remains healthy and functioning properly.
Kidney Transplant Anti-rejection Medications:
Anti-rejection medications are used to prevent the rejection of a kidney transplant by the body. The most common causes for rejection are drug and non-drug related factors such as infection, blood clotting, genetic incompatibility and other conditions like high or low creatinine levels.
Bone Marrow Transplant Anti-rejection Medications:
Bone marrow transplant (BMT) is a procedure done to replace the diseased or damaged bone marrow with healthy donor cells. The most common diseases that require BMT are chronic granulomatous disease, acute granulomatous disease, polycythemia vera (Polycystic Kidney Disease), and myelodysplastic syndrome.
Application Insights:
The hospital pharmacy application segment dominated the global market in 2017. This is attributed to factors such as presence of a large patient base and high prevalence of chronic diseases that require frequent medication. Hospital pharmacies are equipped with all the necessary drugs to treat patients, whereas retail pharmacies may require prior authorization for expensive drugs.
Organ transplantation procedures are majorly performed in hospitals on an outpatient basis owing to advanced medical technology and skilled personnel, which reduces post-operative complications significantly. Organ transplantation requires a series of complex surgical procedures followed by several days or weeks spent at bed rest depending upon the organ being transplanted (liver, kidney). The availability of highly skilled surgeons along with advanced medical technologies has resulted in growth post-surgery treatment through hospital pharmacies thereby contributing towards revenue generation for this segment.
Regional Analysis:
North America dominated the global organ transplant anti-rejection medications market in 2017. This can be attributed to favorable healthcare reimbursement policies, increasing government funding for research & development activities, and rising awareness among patients and physicians regarding organ transplantation procedures. Moreover, a high number of chronic diseases leading to increased mortality rates is also expected to drive the demand for these medications in this region. For instance, according to statistics published by CDC in 2016 - death rate from heart disease has been steadily increasing over the past few years; it was around 591,000 deaths that were recorded that year.
In Asia Pacific as well as Latin America countries there is a significant increase in need of kidney transplants due its high incidence rate of hypertension (high blood pressure).
Growth Factors:
- Increasing incidence of organ failures and the consequent increase in demand for organ transplants is expected to drive the growth of the global organ transplant anti-rejection medications market.
- The increasing use of immunosuppressive drugs for preventing rejection after transplant surgeries is also anticipated to fuel market growth over the forecast period.
- The rising number of clinical trials being conducted for new organ transplant anti-rejection medications is expected to provide a fillip to market growth in the coming years.
- Growing awareness about available treatment options and their benefits is projected to boost demand for these medications in the near future.
- Technological advancements that have led to development of novel and more effective drugs are likely to propel market expansion during the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Organ Transplant Anti-rejection Medications Market Research Report
By Type
Kidney Transplant Anti-rejection Medications, Bone Marrow Transplant Anti-rejection Medications, Liver Transplant Anti-rejection Medications, Heart Transplant Anti-rejection Medications, Lung Transplant Anti-rejection Medications, Other
By Application
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other
By Companies
GSK, Novartis AG, Roche, Astellas Pharma, Inc., Pfizer, AbbVie, Inc., Allergan plc, Bristol-Myers Squibb Company (BMS), Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Organ Transplant Anti-rejection Medications Market Report Segments:
The global Organ Transplant Anti-rejection Medications market is segmented on the basis of:
Types
Kidney Transplant Anti-rejection Medications, Bone Marrow Transplant Anti-rejection Medications, Liver Transplant Anti-rejection Medications, Heart Transplant Anti-rejection Medications, Lung Transplant Anti-rejection Medications, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Novartis AG
- Roche
- Astellas Pharma, Inc.
- Pfizer
- AbbVie, Inc.
- Allergan plc
- Bristol-Myers Squibb Company (BMS)
- Sanofi
Highlights of The Organ Transplant Anti-rejection Medications Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Kidney Transplant Anti-rejection Medications
- Bone Marrow Transplant Anti-rejection Medications
- Liver Transplant Anti-rejection Medications
- Heart Transplant Anti-rejection Medications
- Lung Transplant Anti-rejection Medications
- Other
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Organ Transplant Anti-rejection Medications Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Organ transplant anti-rejection medications are medications that help prevent the body from rejecting a transplanted organ.
Some of the key players operating in the organ transplant anti-rejection medications market are GSK, Novartis AG, Roche, Astellas Pharma, Inc., Pfizer, AbbVie, Inc., Allergan plc, Bristol-Myers Squibb Company (BMS), Sanofi.
The organ transplant anti-rejection medications market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Organ Transplant Anti-rejection Medications Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Organ Transplant Anti-rejection Medications Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Organ Transplant Anti-rejection Medications Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Organ Transplant Anti-rejection Medications Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Organ Transplant Anti-rejection Medications Market Size & Forecast, 2018-2028
4.5.1 Organ Transplant Anti-rejection Medications Market Size and Y-o-Y Growth
4.5.2 Organ Transplant Anti-rejection Medications Market Absolute $ Opportunity
Chapter 5 Global Organ Transplant Anti-rejection Medications Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Organ Transplant Anti-rejection Medications Market Size Forecast by Type
5.2.1 Kidney Transplant Anti-rejection Medications
5.2.2 Bone Marrow Transplant Anti-rejection Medications
5.2.3 Liver Transplant Anti-rejection Medications
5.2.4 Heart Transplant Anti-rejection Medications
5.2.5 Lung Transplant Anti-rejection Medications
5.2.6 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Organ Transplant Anti-rejection Medications Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Organ Transplant Anti-rejection Medications Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Online Pharmacy
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Organ Transplant Anti-rejection Medications Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Organ Transplant Anti-rejection Medications Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Organ Transplant Anti-rejection Medications Analysis and Forecast
9.1 Introduction
9.2 North America Organ Transplant Anti-rejection Medications Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Organ Transplant Anti-rejection Medications Market Size Forecast by Type
9.6.1 Kidney Transplant Anti-rejection Medications
9.6.2 Bone Marrow Transplant Anti-rejection Medications
9.6.3 Liver Transplant Anti-rejection Medications
9.6.4 Heart Transplant Anti-rejection Medications
9.6.5 Lung Transplant Anti-rejection Medications
9.6.6 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Organ Transplant Anti-rejection Medications Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Online Pharmacy
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Organ Transplant Anti-rejection Medications Analysis and Forecast
10.1 Introduction
10.2 Europe Organ Transplant Anti-rejection Medications Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Organ Transplant Anti-rejection Medications Market Size Forecast by Type
10.6.1 Kidney Transplant Anti-rejection Medications
10.6.2 Bone Marrow Transplant Anti-rejection Medications
10.6.3 Liver Transplant Anti-rejection Medications
10.6.4 Heart Transplant Anti-rejection Medications
10.6.5 Lung Transplant Anti-rejection Medications
10.6.6 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Organ Transplant Anti-rejection Medications Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Online Pharmacy
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Organ Transplant Anti-rejection Medications Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Organ Transplant Anti-rejection Medications Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Organ Transplant Anti-rejection Medications Market Size Forecast by Type
11.6.1 Kidney Transplant Anti-rejection Medications
11.6.2 Bone Marrow Transplant Anti-rejection Medications
11.6.3 Liver Transplant Anti-rejection Medications
11.6.4 Heart Transplant Anti-rejection Medications
11.6.5 Lung Transplant Anti-rejection Medications
11.6.6 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Organ Transplant Anti-rejection Medications Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Online Pharmacy
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Organ Transplant Anti-rejection Medications Analysis and Forecast
12.1 Introduction
12.2 Latin America Organ Transplant Anti-rejection Medications Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Organ Transplant Anti-rejection Medications Market Size Forecast by Type
12.6.1 Kidney Transplant Anti-rejection Medications
12.6.2 Bone Marrow Transplant Anti-rejection Medications
12.6.3 Liver Transplant Anti-rejection Medications
12.6.4 Heart Transplant Anti-rejection Medications
12.6.5 Lung Transplant Anti-rejection Medications
12.6.6 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Organ Transplant Anti-rejection Medications Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Online Pharmacy
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Organ Transplant Anti-rejection Medications Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Organ Transplant Anti-rejection Medications Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Organ Transplant Anti-rejection Medications Market Size Forecast by Type
13.6.1 Kidney Transplant Anti-rejection Medications
13.6.2 Bone Marrow Transplant Anti-rejection Medications
13.6.3 Liver Transplant Anti-rejection Medications
13.6.4 Heart Transplant Anti-rejection Medications
13.6.5 Lung Transplant Anti-rejection Medications
13.6.6 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Organ Transplant Anti-rejection Medications Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Online Pharmacy
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Organ Transplant Anti-rejection Medications Market: Competitive Dashboard
14.2 Global Organ Transplant Anti-rejection Medications Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 Novartis AG
14.3.3 Roche
14.3.4 Astellas Pharma, Inc.
14.3.5 Pfizer
14.3.6 AbbVie, Inc.
14.3.7 Allergan plc
14.3.8 Bristol-Myers Squibb Company (BMS)
14.3.9 Sanofi
